VERTEX PHARMACEUTICALS INCORPORATED Vertex Pharmaceuticals Incorporated Share Price
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 430.1 USD | +1.74% |
|
+6.58% | +5.43% |
| 10/05 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| 07/05 | FOMO is Back |  |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.08TCr 90TCr | Sales 2025 * | 1.17TCr 98TCr | Capitalization | 11TCr 9,10500Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 397.7Cr 33TCr | Net income 2025 * | 448Cr 37TCr | EV / Sales 2024 * | 8.84 x |
| Net cash position 2024 * | 1.4TCr 1,16600Cr | Net cash position 2025 * | 1.9TCr 1,58700Cr | EV / Sales 2025 * | 7.71 x |
| P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
24.9
x | Employees | 5,400 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vertex Pharmaceuticals Incorporated
More recommendations
More press releases
More news
| 1 day | +1.74% | ||
| 1 week | +6.58% | ||
| Current month | +9.21% | ||
| 1 month | +7.96% | ||
| 3 months | +3.11% | ||
| 6 months | +13.21% | ||
| Current year | +5.43% |
1 week
394.03
429.29
1 month
391.01429.29
Current year
391.01448.40
1 year
320.01448.40
3 years
176.36448.40
5 years
164.96448.40
10 years
63.60448.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 01/17/01 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08/09/08 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 10/19/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08/17/08 |
Jeffrey Leiden
CHM | Chairman | 68 | 08/09/08 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01/98/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.67% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 429.1 | +1.49% | 566 754 |
| 10/24/10 | 422.8 | +0.90% | 1,064,604 |
| 09/24/09 | 419 | +0.04% | 676,185 |
| 08/24/08 | 418.8 | +2.09% | 1,651,673 |
| 07/24/07 | 410.2 | +1.92% | 1,614,092 |
Delayed Quote Nasdaq, May 14, 2024 at 01:05 am IST
More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
15/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.43% | 11TCr | |
| +11.07% | 11TCr | |
| -0.38% | 2.23TCr | |
| -12.19% | 2.21TCr | |
| -7.66% | 1.87TCr | |
| -36.52% | 1.76TCr | |
| -10.41% | 1.69TCr | |
| +2.85% | 1.38TCr | |
| +35.12% | 1.25TCr | |
| +285.71% | 812.02Cr |
- Stock Market
- Equities
- VRTX Stock